# Low-dose palliative radiotherapy for malignant peripheral T-cell lymphoma masked by cellulitis and osteomyelitis: a case report

**Authors:** Yasir Alayed

PMC · DOI: 10.1093/bjrcr/uaad010 · 2023-12-18

## TL;DR

Low-dose radiotherapy helped manage a rare lymphoma case complicated by infection after chemotherapy failed.

## Contribution

Demonstrates successful use of low-dose palliative radiotherapy in a complex, post-chemotherapy lymphoma case.

## Key findings

- Low-dose radiotherapy provided effective palliation for a rare lymphoma case.
- The case involved a different lymphoma histology after systemic therapy failure.
- Management was complicated by concurrent local infection.

## Abstract

Classic Hodgkin lymphoma is a potentially curable disease. With the advent of effective systemic regimens with adriamycin, bleomycin, vincristine, and dacarbazine, chemotherapy has become the treatment of choice for advanced Hodgkin lymphoma. However, for advanced Hodgkin lymphoma after chemotherapy, disease relapse rates are still high. This case report highlights how low-dose palliative radiotherapy can be used successfully for the management of an unusual case of recurrent lymphoma with a different histology soon after completing systemic therapy, which was further complicated by an ongoing local infection.

## Linked entities

- **Chemicals:** adriamycin (PubChem CID 31703), bleomycin (PubChem CID 5360373), vincristine (PubChem CID 5978), dacarbazine (PubChem CID 135398738)
- **Diseases:** Hodgkin lymphoma (MONDO:0004952), lymphoma (MONDO:0003659), cellulitis (MONDO:0005230), osteomyelitis (MONDO:0005246)

## Full-text entities

- **Diseases:** malignant peripheral T-cell lymphoma (MESH:D016411), Classic Hodgkin lymphoma (MESH:D006689), cellulitis (MESH:D002481), osteomyelitis (MESH:D010019), infection (MESH:D007239), lymphoma (MESH:D008223)
- **Chemicals:** adriamycin, bleomycin, vincristine, and dacarbazine (-)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10860520/full.md

---
Source: https://tomesphere.com/paper/PMC10860520